Tessa to prioritize allogeneic CAR-T cell therapy platform following strong safety and efficacy data presented during ASH 2022SINGAPORE, Jan. 03, 2023 (Tessa), a clinical-stage cell therapy company developing
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023 Tessa to prioritize allogeneic CAR-T cell therapy platform following strong safety and efficacy data presented during ASH 2022 GlobeNewswire January 03, 2023 SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments.
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma GlobeNewswire December 12, 2022 Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete.
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)